Patents by Inventor Maud Léa MAYOUX

Maud Léa MAYOUX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Predicting response to PD-1 axis inhibitors
    Patent number: 11513122
    Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade 5 treatment.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: November 29, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Maud Léa Mayoux, Andreas Roller, Wei Xu
  • ANTIBODIES BINDING TO GPRC5D
    Publication number: 20220259318
    Abstract: The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ALEXANDER BUJOTZEK, TONY CHRISTOPEIT, TANJA FAUTI, GEORG FERTIG, HÉLÈNE CÉCILE HAEGEL, CHRISTIAN KLEIN, THOMAS KRAFT, STEFAN LORENZ, MAUD LÉA MAYOUX, ANNELIESE SCHNEIDER
  • PREDICTING RESPONSE TO PD-1 AXIS INHIBITORS
    Publication number: 20190346444
    Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade treatment.
    Type: Application
    Filed: March 25, 2019
    Publication date: November 14, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Maud Léa MAYOUX, Andreas ROLLER, Wei XU